atorvastatin + rosuvastatin + pitavastatin

This entry refers to a selection of HMG-CoA reductase inhibitors (statins)—specifically atorvastatin, rosuvastatin, and pitavastatin—being evaluated as an adjunctive treatment in combination with progesterone for young women with atypical endometrial hyperplasia (AEH) or early endometrial carcinoma (EEC). In clinical research led by Peking University People's Hospital (NCT04437004), these statins are investigated for their potential synergistic effects with hormonal therapy to improve complete response rates and prevent recurrence in patients seeking fertility-preserving treatment. Statins are hypothesized to inhibit tumor cell proliferation and induce apoptosis in endometrial cancer cells by blocking the mevalonate pathway, which is often upregulated in various malignancies. The term "pivastatin" in the input is a common misspelling of pitavastatin.

Other names

atorvastatin + rosuvastatin + pivastatinstatins + progesterone regimen